Trending

Indivior declares collaboration with Addex Pharma to accelerate GABAB positive allosteric modulators (PAMs). It has previously recorded preclinical efficacy in animal models for alcohol…
Read More...

Taiwan and US based biopharmaceutical company, Foresee pharmaceutical Co., Ltd. ventures into an exclusive license and distribution agreement with an Israel based biopharmaceutical…
Read More...

U.S FDA has accepted the IND application for ASN007, a selective ERK ½ inhibitor as declared by Asana BioSciences which specialises in oncology nd a clinical stage biopharmaceutical…
Read More...

Genecentric Therapeutics Inc. Proclaimed a research collaboration to assess the potential of Genecentric’s Cancer Subtype Platform in order to detect responders to G1 Therapeutic’s oral…
Read More...

Novaquest Capital Management announced acquisition of Viamet Pharmaceuticals including the company’s product candidate, VT-1161 that successfully complete phase 2b clinical trials for…
Read More...

Clinical biopharmaceutical company, Liquidia dedicated to accelerate the performance of precision medicine by accurately engineering drug particles announces to commence the evolution…
Read More...

Pharmaceutical Product Development, LLC asserts Colin Hill, an acclaimed name in the health care technology and a connoisseur in precision medicine to its board of directors. He is…
Read More...

ANI Pharmaceuticals announced that it has acquired the NDAs and U.S. rights to market ATACAND, ATACAND HCT, ARIMIDEX, and CASODEX from AstraZeneca for $46.5 million in cash, royalties,…
Read More...

HyLeukin is an immuno-oncology agent comprised of an optimally engineered Interleukin-7 (IL-7) molecule based on Genexine's proprietary long-acting platform technology. Genexine…
Read More...

Mallinckrodt announced that they have entered into an agreement under which Mallinckrodt will acquire Sucampo, including its commercial and development assets. The transaction was…
Read More...

Teva Pharmaceutical Industries Ltd., announced the exclusive launch of a generic version of Reyataz®1 (atazanavir) capsules in the U.S. Atazanavir sulfate capsules are a protease…
Read More...

Soligenix announced that the United States (US) Patent Office has granted the patent entitled "Novel Peptides and Analogs for Use in the Treatment of Oral Mucositis."  The newly issued…
Read More...